Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV001105606 | SCV001262590 | uncertain significance | Congenital prothrombin deficiency | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Illumina Laboratory Services, |
RCV001105607 | SCV001262591 | uncertain significance | Thrombophilia due to thrombin defect | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Baylor Genetics | RCV001105606 | SCV001528498 | uncertain significance | Congenital prothrombin deficiency | 2018-07-31 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Ambry Genetics | RCV002411630 | SCV002721415 | uncertain significance | Inborn genetic diseases | 2024-06-09 | criteria provided, single submitter | clinical testing | The p.T64M variant (also known as c.191C>T), located in coding exon 2 of the F2 gene, results from a C to T substitution at nucleotide position 191. The threonine at codon 64 is replaced by methionine, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV004792725 | SCV005412314 | uncertain significance | not provided | 2024-05-03 | criteria provided, single submitter | clinical testing | PM1_supporting, PM2_moderate |